Order Article Reprints

Casili G, Scuderi SA, Lanza M, Filippone A, Mannino D, Giuffrida R, Colarossi C, Mare M, Capra AP, De Gaetano F, et al. Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers. 2024; 16(6):1211. https://doi.org/10.3390/cancers16061211

Casili, Giovanna, Sarah Adriana Scuderi, Marika Lanza, Alessia Filippone, Deborah Mannino, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Anna Paola Capra, Federica De Gaetano, and et al. 2024. "Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796" Cancers 16, no. 6: 1211. https://doi.org/10.3390/cancers16061211

Casili, G., Scuderi, S. A., Lanza, M., Filippone, A., Mannino, D., Giuffrida, R., Colarossi, C., Mare, M., Capra, A. P., De Gaetano, F., Portelli, M., Militi, A., Cuzzocrea, S., Paterniti, I., & Esposito, E. (2024). Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796. Cancers, 16(6), 1211. https://doi.org/10.3390/cancers16061211